Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.42 |
| ▸ | KISS1R | Q969F8 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ALPL | P05186 | 1/20 | 0.32 |
| ▸ | MME | P08473 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25927371 | 1.00 | SLC1A3 (0.42) | SLC1A3SLC1A2SLC1A1KISS1RTSHR | |
| SCHEMBL15080401 | 1.00 | SLC1A3 (0.42) | SLC1A3SLC1A2SLC1A1KISS1RTSHR | |
| SCHEMBL25927433 | 0.86 | KISS1R (0.46) | SLC1A3SLC1A2SLC1A1KISS1RTSHR | |
| SCHEMBL13235911 | 0.80 | SLC1A3 (0.42) | SLC1A3SLC1A2SLC1A1KISS1RTSHR | |
| SCHEMBL12973005 | 0.80 | SLC1A1 (0.57) | SLC1A3SLC1A2SLC1A1TSHRCA1 | |
| SCHEMBL3958833 | 0.79 | — | — | |
| SCHEMBL7906853 | 0.78 | ALDH1A1 (0.52) | SLC1A3SLC1A2SLC1A1KISS1RCA1 | |
| SCHEMBL15277787 | 0.78 | SLC1A1 (0.45) | SLC1A3SLC1A2SLC1A1TSHRCA1 | |
| SCHEMBL15080320 | 0.78 | SLC1A3 (0.45) | SLC1A3SLC1A2SLC1A1KISS1RCA1 | |
| SCHEMBL3042219 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | CFD, TFPI, CFH | SLC1A3 3476/4885SLC1A2 3714/4885SLC1A1 3558/4885 |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | SLC1A3 3476/4885SLC1A2 3714/4885SLC1A1 3558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.